



TAF2 Induces Skeletal (Stromal) Stem Cell Migration Through Activation of Rac1-p38 Signaling

Jafari, Abbas; Isa, Adiba; Chen, Li; Ditzel, Nicholas; Zaher, Walid; Harkness, Linda; Johnsen, Hans E.; Abdallah, Basem M.; Clausen, Christian; Kassem, Moustapha

Published in:
Stem Cells

DOI:
[10.1002/stem.2955](https://doi.org/10.1002/stem.2955)

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record


Document license:
[CC BY-NC](#)

Citation for published version (APA):
Jafari, A., Isa, A., Chen, L., Ditzel, N., Zaher, W., Harkness, L., Johnsen, H. E., Abdallah, B. M., Clausen, C., & Kassem, M. (2019). TAF2 Induces Skeletal (Stromal) Stem Cell Migration Through Activation of Rac1-p38 Signaling. *Stem Cells*, 37(3), 407-416. <https://doi.org/10.1002/stem.2955>



Nikon BioImaging Lab

Let us do the imaging for you.



The Nikon BioImaging Lab is a state-of-the-art facility located in Cambridge, Massachusetts, that provides advanced technologies to support the burgeoning regenerative medicine and biotech sector.

For more information, visit www.microscope.healthcare.nikon.com/bioimaging-lab



Nikon Instruments Inc. ■ www.microscope.healthcare.nikon.com ■ nikoninstruments@nikon.net

^aDepartment of Cellular and Molecular Medicine, Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark;

^bMolecular Endocrinology & Stem Cell Research Unit (KMEB), Department of Endocrinology and Metabolism, Odense University Hospital & University of Southern Denmark, Odense, Denmark;

^cStem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Saudi Arabia;

^dDepartment of Haematology, Aalborg University, Aalborg, Denmark;

^eBiological Sciences Department, College of Science, King Faisal University, Hofuf, Saudi Arabia; ^fBioneer A/S, Hørsholm, Denmark

*Contributed equally.

†Deceased.




Correspondence: Abbas Jafari, Ph.D., Department of Cellular and Molecular Medicine, Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), University of Copenhagen, Copenhagen, Denmark. e-mail: ajafari@sund.ku.dk; or Moustapha Kassem, M.D., Ph.D., Molecular Endocrinology & Stem Cell Research Unit (KMEB), Department of Endocrinology and Metabolism, Odense University Hospital & University of Southern Denmark, Odense, Denmark. e-mail: mkassem@health.sdu.dk

Received May 16, 2018; accepted for publication October 25, 2018; first published online in *STEM CELLS EXPRESS* November 28, 2018.

<http://dx.doi.org/10.1002/stem.2955>

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

TFAA2 Induces Skeletal (Stromal) Stem Cell Migration Through Activation of Rac1-p38 Signaling

ABBAS JAFARI ^{a,b,*} ADIBA ISA,^{b,*} LI CHEN ^b NICHOLAS DITZEL,^b WALID ZAHER,^{b,c} LINDA HARKNESS,^b HANS E. JOHNSEN,^{d,†} BASEM M. ABDALLAH,^{b,e} CHRISTIAN CLAUSEN,^f MOUSTAPHA KASSEM ^{a,b,c}

Key Words. Mesenchymal stem (stromal) cell • Migration • Fracture healing • Regenerative medicine • TFAA2

ABSTRACT

Understanding the mechanisms regulating recruitment of human skeletal (stromal or mesenchymal) stem cells (hMSC) to sites of tissue injury is a prerequisite for their successful use in cell replacement therapy. Chemokine-like protein TFAA2 is a recently discovered neurokinine involved in neuronal cell migration and neurite outgrowth. Here, we demonstrate a possible role for TFAA2 in regulating recruitment of hMSC to bone fracture sites. TFAA2 increased the *in vitro* trans-well migration and motility of hMSC in a dose-dependent fashion and induced significant morphological changes including formation of lamellipodia as revealed by high-content-image analysis at single-cell level. Mechanistic studies revealed that TFAA2 enhanced hMSC migration through activation of the Rac1-p38 pathway. In addition, TFAA2 enhanced hMSC proliferation, whereas differentiation of hMSC toward osteoblast and adipocyte lineages was not altered. *in vivo* studies demonstrated transient upregulation of TFAA2 gene expression during the inflammatory phase of fracture healing in a closed femoral fracture model in mice, and a similar pattern was observed in serum levels of TFAA2 in patients after hip fracture. Finally, interleukin-1 β was found as an upstream regulator of TFAA2 expression. Our findings demonstrate that TFAA2 enhances hMSC migration and recruitment and thus is relevant for regenerative medicine applications. *STEM CELLS* 2019;37:407–416

SIGNIFICANCE STATEMENT

Skeletal (mesenchymal) stem cells (MSC) are being used in an increasing number of clinical trials for their therapeutic benefits in tissue regeneration. Understanding the mechanisms that regulate MSC migration and homing is a prerequisite for their successful use in cell therapy applications. Results show that TFAA2, a recently identified neurokinine, is highly expressed at the site of skeletal fracture and induces MSC migration through activation of Rac1/p38 signaling.

INTRODUCTION

Skeletal (also known as bone marrow stromal or mesenchymal) stem cells (MSC) are nonhematopoietic cells residing in the bone marrow stroma and are capable of differentiation to mesodermal cell types such as osteoblasts, adipocytes, and chondrocytes [1,2]. MSC are recruited to the bone formation sites during bone remodeling and after bone fracture, where they differentiate into osteoblastic bone-forming cells [3]. Insufficient or defective recruitment of MSC to bone formation sites has been suggested as a mechanism mediating impaired bone formation in osteoporosis and in nonunion or poorly healing fractures [4,5].

MSC are being tested in an increasing number of clinical trials for enhancing tissue regeneration, including bone tissue regeneration,

where direct transplantation of MSC cultured on scaffolds has been tested with good preliminary results [6–8]. Systemic (intravenous) infusion of MSC is an attractive route of administration because of its ease and clinical feasibility [6–8]. Also hematopoietic stem cell (HSC) transplantation has demonstrated the ability of HSC to home to their bone marrow niche after intravenous infusion and to exert their biological functions [9], suggesting that MSC may be equipped with similar functional capacity.

Previous studies have demonstrated the presence of MSC in the circulation and that they can be recruited to injured tissues (for review, please see [10]). MSC can adhere to endothelial cells and exhibit leukocyte-like trans-endothelial migration [11]. However, few cells are recruited to fracture sites after systemic infusion of MSC [12,13]. Interestingly,

some studies have reported enhanced tissue regeneration despite the presence of few engrafted MSC [14–17]. To increase the number of MSC homed to the bone, a number of approaches have been tried, for example, modifying CD44 expression by MSC [18] or surface conjugation of MSC with a synthetic peptidomimetic ligand with high affinity for activated $\alpha 4 \beta 1$ integrin to target MSC to the skeleton [19] or to precondition MSC with small molecules before systemic infusion in order to boost their skeletal homing properties [12].

In order to identify secreted factors with capacity for enhancing recruitment of MSC to the skeleton, we examined a number of factors known to regulate migration and motility of adult stem cells in a number of tissues. We identified TFAA2 in a screening experiment using chemoattraction of MSC as an endpoint. TFAA2 (also known as FAM19A2, family with sequence similarity 19 member A2) is a member of FAM19A family consisting of five highly homologous genes (TFAA1–5) encoding small secreted proteins [20]. TFAA proteins are broadly expressed with highest expression in the brain and function as neurokinins [20]. Despite lack of functional studies about biological roles of TFAA2, genome-wide association studies have revealed an association between TFAA2 gene polymorphism and mental retardation and insulin sensitivity [21, 22]. Here, we report a novel role for TFAA2 in recruiting human MSC (hMSC) to the site of skeletal fracture. Using cell-based and in vivo studies, we show that TFAA2 stimulates hMSC migration through activation of Rac1-p38 signaling. TFAA2 overexpression at the site of skeletal fracture increased the number of recruited hMSC to the injured tissue. TFAA2 levels were differentially regulated during the time course of fracture healing in a closed femoral fracture model in mice, and a similar pattern was observed in TFAA2 serum levels in patients with hip fractures.

MATERIALS AND METHODS

MSC Culture

As a model for primary hMSC, we used our well-characterized, immortalized human MSC line (hereafter referred to as hMSC), established by ectopic expression of the catalytic subunit of human telomerase as previously described [40]. hMSC maintain all typical characteristics of primary hMSC [41]. Primary bone marrow-derived hMSC (hereafter referred to as hpMSC) were established from fresh bone marrow aspirates as previously described, from three young healthy donors after informed consent [42]. The cells were cultured in a standard growth medium containing minimal essential medium (MEM; Gibco, Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Biochrom, Germany) and 1% penicillin/streptomycin (Gibco, UK) at 37°C in a humidified atmosphere containing 5% CO₂. The medium was changed every third day until the cells became 90% confluent.

Boyden Chamber Chemotaxis Trans-Well Migration Assay

The migration ability of hMSC toward a number of chemoattractant factors identified by NeuroSearch A/S, Copenhagen, Denmark, and provided by Dr. Per Horn was measured in a 48-well microchemotaxis Boyden chamber-based cell migration assay (8 μ m pores, polycarbonate membrane, NeuroProbe, Inc., USA). The membrane was coated for 1 hour at 37°C with migration media (low glucose Dulbecco's MEM [LG-DMEM,

Gibco]), supplemented with 0.2% FBS (Gibco) containing 5 μ g/ml fibronectin and 10 μ g/ml rat tail collagen I. hMSC were serum starved in migration media 24 hours before migration assay. The chemotaxis and control media (27 μ l) were placed in the lower chamber and covered by the coated membrane and fixed by the upper chamber. hMSC (1.25×10^4) suspended in 50 μ l migration media were loaded into each well of the upper chamber. The migration was carried out for 4 hours in 37°C. Nonmigrated cells on the upper side of the membrane were scraped and rinsed with cold phosphate buffered saline (PBS). Migrated cells on the lower side of the membrane were fixed and stained with hemacolor staining kit (Merck, Germany). The migrated cells were scanned and photos were taken at $\times 20$ magnification by a computer-assisted cell-counting system (Visiopharm, Denmark). Images were captured of the entire wells and counted by using ImageJ software. Results were expressed as mean number of cells per at least six replicates and three independent experiments. For inhibition of the signaling pathways, the cells were incubated 30 minutes before the seeding in the chambers, with p38 inhibitor SB203580 (Sigma) or dimethyl sulfoxide (DMSO) (Sigma, USA) used as vehicle.

Oris Cell Motility Assay

The assay was performed according to the manufacturer's instructions (Platypus, Madison, WI). Briefly, 96-well cell culture plates were coated with fibronectin (10 μ g/ml) in PBS for 2 hours at 37°C, rinsed twice with PBS. After washing, the Oris cell seeding stoppers were inserted in the wells. hMSC were trypsinized, washed twice with MEM, and resuspended in 0.2% serum medium, seeded and permitted to attach at a density of 2.5×10^3 cells in each well. Thereafter, the stoppers were gently lifted from all wells excluding the designated "reference" wells ($n = 6$). Then, cells were washed with migration media (LG-DMEM, supplemented with 0.2% FBS) and permitted to migrate during 24 hours in fresh migration media supplemented with chemoattractant in a humidified chamber (37°C, 5% CO₂). The cells were washed and fixed for 10 minutes in 4% paraformaldehyde/PBS, permeabilized with 0.1% Triton X-100 in PBS and stained with tetramethylrhodamine (TRITC)-conjugated phalloidin solution for 40 minutes followed by 4',6-diamidino-2-phenylindole (DAPI; 1 μ g/ml). The mean fluorescence intensity of the migrated cells was analyzed by an enzyme-linked immunosorbent assay (ELISA) microtiter plate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany).

Quantitation of Cell Spreading and Immunofluorescent Intensity

Ninety-six-well cell culture plates (Perkin Elmer, Denmark) were coated with fibronectin (10 μ g/ml) in PBS for 2 hours at 37°C, rinsed twice with PBS, and blocked with 1% BSA for 1 hour. hMSC were trypsinized, washed twice with MEM media, and resuspended in serum-free medium. Cells were stimulated with 10 μ g/ml TFAA2 (R&D systems, Minneapolis, MN) for 30 minutes at 37°C and then replated onto fibronectin-coated plates in standard culture medium. Cells were fixed in 4% paraformaldehyde for 10 minutes, washed with PBS, and stained for F-actin with phalloidin (TRITC-labeled, Sigma) and DAPI for nuclear staining. Fluorescent images were analyzed by Operetta high-content-imaging system (Perkin Elmer) at $\times 20$ magnification using Harmony High Content Imaging and Analysis Software (PerkinElmer).

Western Blotting Analysis

hMSC were cultured until 80% confluent, then starved in migration media for 24 hours before treatment with TFAA2 at 10 µg/ml or 10% FBS. Protein samples were harvested at 0, 10, 30, 60, 120, and 240 minutes after treatment. Briefly, cells were washed in PBS and lysed in RIPA buffer (Sigma, USA) supplemented with protease and phosphatase inhibitors (Roche, Germany). After 30 minutes incubation at 4°C, samples were centrifuged for 10 minutes at 12,000 rpm, 4°C. Protein concentration was determined with Pierce Coomassie Plus Bradford assay (Thermo Fisher Scientific, USA), and equal amounts of proteins were loaded on a 10% polyacrylamide gel (Novex, Life technologies, USA). Blotted nitrocellulose membranes were incubated overnight with antibodies against P-p38, p38, P-AKT, AKT, P-ERK, ERK2 (Cell Signaling, USA), and α-tubulin (Sigma, USA), overnight at 4°C. Membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology, USA) for 45 minutes at room temperature, and protein bands were visualized with Amersham ECL chemiluminescence detection system (GE Healthcare, UK).

In Vivo Studies of Fracture Healing

The ethical approval for femur fracture in mice was granted by the Danish National Animal Experiment Inspectorate (2012-15-2934-00559). Female immunodeficient NOD.CB17-Prkdc^{scid}/J (NOD-scid, 12 weeks old) and C57BL/6J (10 weeks old) mice were anesthetized by administration of intraperitoneal ketamine hydrochloride (100 mg/kg body weight) and xylazine hydrochloride (10 mg/kg). The closed femur fracture procedure was carried out as described [45]. Briefly, an incision was made just medial to the patella, and the fracture was fixed by inserting a 0.5 mm needle between the condyles and drilled in a retrograde fashion into the medullary cavity of the femur. Afterward, a standardized reproducible closed fracture was induced using a blunt-impact guillotine fracture apparatus. A radiograph was acquired after fracture induction (using Faxitron MX-20; Faxitron, USA) to confirm the fracture induction and needle position.

Immunohistochemical Staining

Tissues were harvested at different time points and fixed in 4% formalin for 3 days. Bones were decalcified in formic acid. The tissue was paraffin embedded, sectioned, and stained for human TFAA2 protein expression. Briefly, the staining was performed using DAKO En Vision+ and PowerVision according to manufacturer's instructions. The tissue sections were demasked using TEG solution (Tris 10 mM, EGTA 0.5 mM, pH 9.0) (15 minutes) and incubated 1 hour with sheep anti-human TFAA2 antibodies (R&D Systems, Abingdon, U.K.) diluted in ChemMate Antibody diluent (1:30 Dako, Glostrup, Denmark). After washing, the sections were incubated with secondary antibody (rabbit anti-goat antibody, cell signaling, USA) for 20 minutes. The slides were processed on an automatic slide processor (Techmate500, Dako, Glostrup, Denmark). Analysis was carried out on an IX50 Olympus microscope using Olympus DP Software v3.1 (Olympus, Essex, U.K.) or a Leica DM4500 (Leica, Wetzlar, Germany) using the Surveyor Turboscan Mosaic acquisition imaging analysis system v5.04.01 (Objective Imaging Ltd, Cambridge, U.K.).

Antibody Labeling and Flow Cytometry Analysis

The cells were incubated with antibodies against cell surface proteins for 20 minutes on ice, and two washes with PBE (PBS containing 2 mM EDTA and 0.5% FBS) were done to remove unbound antibody. For intracellular staining of TFAA2, the cells were fixed and permeabilized with BD-fixation and permeabilization kit (BD Biosciences, USA), and the cells were stained with 2 µg anti-TFAA2 antibodies and incubated for 1 hour on ice in dark. Cells were washed, fixed in 2% paraformaldehyde, and cell acquisition was performed with flow cytometer BD FACS LSRII. Kaluza 1.2 software program was used for analysis of the data. Mean fluorescence intensity (MFI) value of a relevant isotype control staining was subtracted from the corresponding MFI of the specific staining. The flow cytometer was standardized by using positive and negative controls and flow check beads each time to reduce day-to-day variation.

RNA Extraction and Quantitative Reverse Transcription Polymerase Chain Reaction

RNA was isolated from organs or cultured cells according to previously published method. [43] After cDNA synthesis, quantitative reverse transcription polymerase chain reaction was performed using a comparative Ct method [$1/(2^{\Delta Ct})$] formula, and data were represented as relative expression to the *HPRT1* reference gene.

Osteoblast Differentiation and ALP Activity Assay

Osteogenic induction was performed using MEM supplemented with 10 mM β-glycerophosphate (Calbiochem-Merck, Germany), 50 µg/ml L-ascorbic acid-2-phosphate (Wako Chemicals GmbH, Germany), 10 nM dexamethasone (Sigma-Aldrich, Denmark), and 10 nM calcitriol (1.25-dihydroxy vitamin-D3) kindly provided by Leo Pharma, Ballerup, Denmark. Medium was changed every third day during induction. The induction was performed with and without addition of different concentrations of rhTFAA2 protein. ALP activity was measured at day 6 of induction. Simultaneously, the numbers of viable cells were determined on the day of ALP activity measurement by adding the CellTiter-Blue solution (Promega, USA) to the wells. The cells were then rinsed with TBS (20 mM Trizma base, 150 mM NaCl at pH = 7.5) and fixed in 3.7% formaldehyde-90% ethanol for 30 seconds at room temperature. A reaction mixture containing 100 µl 50 mM NaHCO₃, 1 mM MgCl₂ (Sigma, USA), and 1 mg/ml of p-nitrophenyl phosphate (Sigma) was added into each well and incubated 20 minutes at 37°C. The reaction was stopped by adding 50 µl of 3 M NaOH. The absorbance at 405 nm was determined using an ELISA microtiter plate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany). ALP enzymatic activity was normalized to the number of viable cells. After osteoblastic induction at day 15, assessment of hydroxyapatite deposition was performed using the OsteoImage Bone Mineralization Assay (Lonza, USA) according to manufacturer's instructions. Data were analyzed, and noninduced cells were compared with induced and induced cells supplemented with rhTFAA2 (10 µg/ml).

Adipogenic Differentiation

Adipogenic differentiation of hMSC was induced using MEM supplemented with 10% FBS (Sigma-Aldrich, Brøndby, Denmark), 10% horse serum (Sigma-Aldrich, USA), 100 nM dexamethasone

(Sigma-Aldrich, Denmark), 500 μ M 1-methyl-3-isobutylxanthine (IBMX, Sigma-Aldrich, USA), 1 μ M rosiglitazone (BRL49653, Cayman Chemical, Ann Arbor, MI), and 5 μ g/ml insulin (Sigma-Aldrich, USA) for 15 days. Media was changed every third day, and rhTFAF2 (10 μ g/ml) was added to induced cells. Oil Red O staining and quantification was performed as previously described [43].

siRNA Transfection

siRNA transfection was performed using a reverse transfection protocol as previously described [42]. Briefly, Lipofectamine 2000 was used as transfection reagent, and transfections were carried out according to the manufacturer's instructions (Invitrogen, USA). Nontargeting siRNA No.2 (Ambion, CA, USA) and siRNA against Rac1 (sense: CUACUGUCUUUGACAAUAtt) (Ambion) were used at 25 nM.

ELISA Measurement of TFAF2 Concentrations in Clinical Samples

ELISA measurements of TFAF2 concentrations in human serum samples were performed using an established ELISA procedure (Mybiosource, San Diego, USA) according to the manufacturer's instructions. The human serum samples used in this study were from patients with traumatic hip fracture admitted to the Orthopaedic Department at Herlev Hospital. The experimental protocol was approved by the regional scientific ethical committee in Copenhagen (Number KA 05081). All patients received oral and written information and participated under signed informed consent. Collection and handling of the serum samples was previously published [44].

RESULTS

TFAF2 Enhanced Migration and Motility of hMSC

To identify novel regulators of hMSC recruitment to injured tissues, we screened a number of newly identified chemoattractant neurokines, for their ability to enhance *in vitro* trans-well migration of hMSC using a three-dimensional-Boyden chamber assay. The members of TFAF family, TFAF2, 4, and 5, exhibited the highest chemoattractant activity for hMSC (Fig. 1A). Next, we used the Oris assay to confirm the trans-well migration-stimulating activity of TFAF proteins and found that TFAF2 is the most potent stimulator of hMSC motility (Fig. 1B, 1C). TFAF2 also stimulated cell motility in cultures of human primary bone marrow-derived MSC (hpMSC; Fig. 1D). To specify whether TFAF2-induced cell migration is directional (chemotaxis) or random (chemokinesis), TFAF2 was added to both upper and lower compartments of the Boyden chamber and we observed a significant reduction in number of migrating hMSC (Fig. 1E) and hpMSC (Fig. 1F). TFAF2 exhibited a dose-dependent chemoattractant effect on the trans-well migration of hMSC (Fig. 1G), and a similar effect was observed in hpMSC (Fig. 1H, 1I). In addition, combining TFAF2 with different concentrations of anti-human TFAF2 antibody reduced the chemotactic activity of TFAF2 (Fig. 1J).

TFAF2 Stimulates hMSC Migration Through Activation of Rac1-p38 Signaling

Formation of lamellipodia is an early event initiating migration of various cell types such as fibroblasts and leukocytes [23]. We used the Operetta high-content-imaging system to perform

quantitative analysis of TFAF2-induced morphological changes in cultured hMSC at a single-cell resolution. We noted that TFAF2 induced formation of lamellipodia (cell protrusions that are needed for cell movement) in cultured hMSC (Fig. 2A) that was associated with increased cell area (Fig. 2B). We then examined the activation status of Rac1 GTPase that is required for formation of lamellipodia and cell migration. Analysis of lysates from TFAF2-stimulated hMSC showed significantly increased levels of Rac1 activity at 10, 15, and 30 minutes after TFAF2 stimulation, which returned to the initial levels after 60 minutes (Fig. 2C). To examine the role of Rac1 in TFAF2-induced hMSC migration, we performed small interfering RNA (siRNA)-mediated knockdown of Rac1, which decreased Rac1 expression in hMSC cultures (Fig. 2D) and abolished the TFAF2-induced hMSC trans-well migration (Fig. 2E). To identify the downstream signaling pathways involved in TFAF2-mediated hMSC motility, we examined the activation status of several signaling factors involved in cell migration: p38, AKT, and ERK. We found increased levels of P-p38 within the initial 2 hours after TFAF2 stimulation (Fig. 2F; Supporting Information Fig. S1). We did not detect changes in P-Akt and P-ERK levels in TFAF2-stimulated hMSC cultures (Fig. 2F). Interestingly, inhibition of p38 signaling using SB203580 abolished TFAF2-induced hMSC migration in a dose-dependent manner (Fig. 2G, 2H).

TFAF2 Regulates Proliferation, but Not Differentiation of hMSC

To investigate other possible functions of TFAF2 in hMSC biology, we tested whether TFAF2 could exert a regulatory effect on hMSC proliferation or differentiation. Adding TFAF2 to hMSC cultures in the presence of normal culture media increased cell proliferation as shown by increased cell number and Ki67 levels (Fig. 3A, 3B). Next, we examined TFAF2 expression during *ex vivo* differentiation of hMSC toward osteoblastic and adipocytic lineages. TFAF2 mRNA expression increased during osteoblast and adipocyte differentiation of hMSC (Fig. 3C, 3D). However, TFAF2 did not affect osteoblast differentiation as shown by quantitation of alkaline phosphatase (ALP) activity (Fig. 3E, 3F) and mineralized matrix formation assessed by measuring deposition of hydroxyapatite (Fig. 3G, 3H). Similarly, TFAF2 did not affect adipocyte differentiation of hMSC evidenced by measuring the number of mature lipid-filled adipocytes (Fig. 3I, 3J).

TFAF2 Levels Are Differentially Regulated During Fracture Healing

To determine the relevance of TFAF2 to pathophysiology of fracture healing, we examined the pattern of TFAF2 expression at different phases of fracture healing in the mouse femoral fracture model. TFAF2 was highly expressed at the site of fracture 48 hours post induction. TFAF2 immunoreactivity was present in the fracture line-adjacent bone marrow and in the injured muscle tissue above the fracture line, where the blunt impact from a dropped weight induced the mid-diaphysis fracture (Fig. 4A). Interestingly, TFAF2 protein expression was already increased 2 hours after the fracture and expression peaked during the first week of fracture (Fig. 4B). TFAF2 mRNA and protein expression was also differentially regulated, with an initial increase in the early phase of fracture healing followed by downregulation (Fig. 4C, 4D). A similar pattern of expression was observed for the pro-inflammatory cytokine




Figure 1. TFA2-enhanced migration of human skeletal (stromal, mesenchymal stem) cells (hMSC). **(A):** Screening of a number of secreted neurokinins (25 µg/ml) for chemotactic activity in hMSC cultures using an in vitro three-dimensional-Boyden chamber trans-well migration assay. Data represent mean \pm SEM from six independent experiments. **, $p \leq .01$, two-tailed unpaired Student *t* test. **(B, C):** Measuring two-dimensional (2D) migration of hMSC in the presence of TFA2, TFA4, and TFA5 (10 µg/ml) using Oris cell migration assay. Scale bar: 50 µm. Data represent mean \pm SEM from three independent experiments. *, $p \leq .05$; **, $p \leq .01$, two-tailed unpaired Student *t* test. **(D):** 2D migration of primary hMSC (hpMSC) in the presence of TFA2 (10 µg/ml) using Oris cell migration assay. Scale bar: 50 µm. Data represent three independent experiments. Quantitation of trans-well migration of hMSC **(E)** and hpMSC **(F)** in the presence of recombinant human TFA2 (10 µg/ml) in different compartments of Boyden chamber assay, LC and UC. Data represent mean \pm SEM from three independent experiments **, $p \leq .01$, two-tailed unpaired Student *t* test. Quantitation of trans-well migration of hMSC **(G)** and hpMSC **(H)** in the presence of different doses of TFA2 (10 ng/ml, 100 ng/ml, 1 µg/ml, and 10 µg/ml). Data represent mean \pm SEM from three independent experiments. *, $p \leq .05$; **, $p \leq .01$, two-tailed unpaired Student *t* test. **(I):** Hemacolor staining of migrated cells toward different concentrations of TFA2 (10 ng/ml, 100 ng/ml, 1 µg/ml, and 10 µg/ml) was present in the lower compartment of the Boyden chamber. Scale bar: 50 µm. Data are representative of three independent experiments. **(J):** Measuring hMSC trans-well migration in the presence of TFA2 (10 µg/ml) with and without anti-human TFA2 antibody (2.5 and 5 µg/ml). Data represent mean \pm SEM from three independent experiments. **, $p \leq .01$, two-tailed unpaired Student *t* test. Abbreviations: LC, lower chamber; UC, upper chamber.

interleukin-1 β (IL-1 β) (Fig. 4E). To investigate the role of IL-1 β as an upstream regulator of TFA2 expression, we added different doses of IL-1 β to hMSC cultures and observed an enhancing effect on TFA2 mRNA and protein levels (Fig. 4F, 4H). We then determined the cellular map of TFA2 expression within the bone marrow during fracture healing. Interestingly, intracellular expression of TFA2 in different leukocyte subpopulations was detectable with high levels of TFA2 expression in monocytes and T cells at day 1 postfracture that was downregulated by day 3 (Fig. 4I), while monocyte cell frequency was not altered, and T-cell frequency was increased on day 3 postfracture compared to day 1 (Fig. 4J). To extrapolate these findings to human physiology, we assessed the kinetics of TFA2 levels in consecutive serum samples from

patients after hip fracture. TFA2 serum levels were high at the first day after hip fracture and decreased gradually in the subsequent measurements during a 21 day observation period (Fig. 4K).

DISCUSSION

In the present study, we identified the neurokinin TFA2 as a novel chemoattractant factor for hMSC that is expressed during the inflammatory phase of bone fracture healing and enhances in vitro transmigration of hMSC. Because of the limited number of factors known to exert specific effects on MSC migration and recruitment capacity, studying the role of TFA2 in MSC




Figure 2. TFAA2-induced lamellipodia formation and enhanced Rac1-p38 signaling in cultures of human skeletal (mesenchymal, stromal) stem cells (hMSC). **(A, B):** Analysis of cell morphology of phalloidin-stained hMSC cultures using Operetta high-content imaging system and cell area quantitation at single-cell level. Scale bar: 10 μ m. Data represent mean \pm SEM from three independent experiments. *, $p \leq .05$, two-tailed unpaired Student t test. **(C):** Quantitation of Rac1 activity in hMSC cultures, 10, 15, 30, and 60 minutes after stimulation with TFAA2 (10 μ g/ml). **(D):** Quantitative reverse transcription polymerase chain reaction analysis of Rac1 expression in hMSC cultures transfected with siRac1 or siCtrl. Data represent mean \pm SEM from three independent experiments. **, $p \leq .01$, two-tailed unpaired Student t test. **(E):** Quantitation of TFAA2-induced trans-well migration of hMSC transfected with siCtrl or siRac1. Data represent mean \pm SEM from three independent experiments. *, $p \leq .05$; **, $p \leq .01$, two-tailed unpaired Student t test. **(F):** Western blot analysis of P-p38, p38, P-Akt, Akt, P-ERK, ERK, and tubulin in lysates from hMSC cultures at different time points after stimulation with TFAA2 (10 μ g/ml) or 10% fetal bovine serum. Data are representative of two independent experiments. **(G, H):** Quantitation of TFAA2-induced trans-well migration in hMSC cultures pretreated with vehicle or p38 small molecule inhibitor (SB203580; 10 and 20 μ M). Photomicrographs show Hemacolor staining of the migrated hMSC. Scale bar: 50 μ m. Data represent mean \pm SEM from three independent experiments. **, $p \leq .01$, two-tailed unpaired Student t test. Abbreviation: ARBU, arbitrary unit; siCtrl, control nontargeting small interfering RNA; siRac1, small interfering RNA against Rac1.

biology is relevant for better understanding the biological processes of bone remodeling and fracture healing as well as possible use for enhancing MSC recruitment to injured sites in regenerative medicine protocols.

TFAA2 is a member of the *TFAA* gene family comprising newly described chemoattractant neurokinines with high expression in the central nervous system. The *TFAA* family is composed of five highly homologous genes encoding small secreted proteins that contain conserved cysteine residues at fixed positions [20]. The *TFAA* family is related to the chemokine, macrophage inflammatory protein-1 α (MIP1 α /CCL3) that plays a role in

granulocyte recruitment to sites of neuroinflammation [24]. Several C-C chemokines ligands, such as CCL3 [24], CCL4/MIP- β [25], and CCL2/Monocyte chemoattractant protein-1 (MCP-1) [26], are known for their modulatory functions on the migration of endogenous or transplanted neural progenitors toward damaged areas of the brain in ischemic stroke.

We observed that in vitro treatment of hMSC with TFAA2 resulted in enhanced trans-well migration as well as significant changes in cell morphology and cytoskeletal remodeling as defined by rearrangement of F-actin to form cell protrusions (lamellipodia) that are needed for cell movement [27].




Figure 3. TFAA2-enhanced proliferation, but not differentiation, of human skeletal (mesenchymal, stromal) stem cells (hMSC). **(A):** Cell number count in hMSC cultures at the baseline (day 0) or in the presence of vehicle or TFAA2 (10 μ g/ml) for 6 days. Data represent mean \pm SEM from three independent experiments. *, $p \leq .05$, two-tailed unpaired Student t test. **(B):** Flow cytometry analysis of Ki67 levels in hMSC cultures in the presence of vehicle or TFAA2 (10 μ g/ml). TFAA2-treated hMSC was also analyzed using isotype control antibody. **(C, D):** Quantitative reverse transcription polymerase chain reaction analysis of TFAA2 mRNA expression during osteoblast and adipocyte differentiation of hMSC. Data represent mean \pm SEM from three independent experiments. **, $p \leq .01$, two-tailed unpaired Student t test. **(E, F):** Quantitation of ALP activity and ALP staining of osteogenic hMSC cultures 6 days after induction of differentiation. Data represent mean \pm SEM from three independent experiments. **(G, H):** Analysis of mineralized matrix formation in osteogenic hMSC cultures by quantitation of hydroxyapatite deposition using Osteoimage bone mineralization assay on day 15 of differentiation. Scale bar: 100 μ m. Data represent mean \pm SEM from three independent experiments. **, $p \leq .01$, two-tailed unpaired Student t test. **(I, J):** Quantification of mature adipocytes by measuring accumulated lipid droplets in the presence of adipocyte induction medium using Oil Red O staining (day 15). Scale bar: 50 μ m. Data represent mean \pm SEM from three independent experiments. **, $p \leq .01$, two-tailed unpaired Student t test. Abbreviations: ALP, alkaline phosphatase; CM, culture media; DAPI, 4',6-diamidino-2-phenylindole; HA, hydroxy apatite; OIM, osteoblast induction media; AIM, adipocyte induction media.

These responses are similar to changes in cell shape and cytoskeleton induced by chemokines known to affect cell motility [28]. Also, previous studies have demonstrated that MSC can respond to chemoattractant proteins by reorganizing their actin cytoskeletons and become polarized in the direction of the chemoattractant gradient [29,30]. Indeed, a disorganization of cytoskeletal F-actin has been associated with impaired migration of not only MSC but also epidermal cells and dendritic cells [31–33]. Formation of lamellipodia and membrane polarization at the leading edge of a migrating cell enables directional cell movement [27]. TFAA2 treatment of hMSC in two dimensional (2D) cultures resulted in formation of lamellipodia in a nondirectional fashion. It is plausible that restoration of Rac1 activity to initial levels at 60 minutes after treatment with TFAA2 represents a 2D-

culture phenomenon because of the absence of directional migration. In addition, the chemoattractant effect of TFAA2 was associated with increased activity of the p38 signaling which is known to mediate the migration of stem cells by several chemotactic factors including: IL-33 [34], stromal cell-derived factor 1 alpha (SDF-1 α) [35,36], and transforming growth factor beta (TGF- β) [37]. It is plausible that p38 signaling is induced after TFAA2 interaction with a cognate receptor that remains to be determined.

We observed that TFAA2 is constitutively expressed in the bone marrow by leukocyte and MSC, and its expression is upregulated after in vitro osteoblast differentiation of MSC. In contrast to several other factors, TFAA2 does not affect differentiation capacity of the cells but enhances their proliferation, which is consistent with a role in enhancing cell recruitment to




Figure 4. TFAF2 levels are regulated during the process of fracture healing. (A): Immunohistochemical analysis of TFAF2 protein expression in a fractured femur, 48 hours after induction of fracture. Scale bar: 1 mm. (B): Analysis of TFAF2 immunoreactivity at the fracture site (boxed area from A) at different time points (2, 24, and 48 hours, 4 days, and 1 week) after induction of femoral fracture (upper panel) and nonfractured femur (lower panel). Scale bar: 100 μ m. (C): Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of TFAF2 mRNA expression in nonfractured and fractured mouse femur at different time points after fracture induction (2 hours, day 1, day 4, and day 14). (D): Flow cytometry analysis of TFAF2 protein expression in bone marrow cells obtained from fractured femur at different time points. Data represent MFI \pm SEM from three independent experiments. **, $p \leq .01$; two-tailed unpaired Student t test. (E): qRT-PCR analysis of IL-1 β mRNA expression in mouse femur before fracture and at different time points after fracture induction (2 hours, day 1, day 4, and day 14). (F): qRT-PCR analysis of TFAF2 mRNA expression in human skeletal (mesenchymal, stromal) stem cell (hMSC) cultures in the presence of different doses of IL-1 β (1, 10, and 50 ng/ml) for 48 hours. Data represent three independent experiments \pm SEM; **, $p \leq .01$, two-tailed paired Student t test. (G, H): Western blot analysis and quantification of TFAF2 protein levels in hMSC cultures in the presence of different doses of IL-1 β . Data represent mean \pm SEM from four independent experiments. *, $p \leq .05$, two-tailed unpaired Student t test. (I, J): Flow cytometry analysis of TFAF2 protein expression and percentage of leukocytes (CD45 $^{+}$), monocytes (CD14 $^{+}$), T cells (CD3 $^{+}$), and B cells (CD19 $^{+}$) at 1 and 3 days postfracture. Data are obtained from pooled bone marrow cells isolated from fractured femurs of three mice. (K): Enzyme-linked immunosorbent assay measurement of TFAF2 levels in consecutive serum samples from patients with hip fracture. **, $p \leq .01$, two-tailed paired Student t test. (L): Proposed model for role of TFAF2 in recruiting MSC to the site of fracture. Abbreviations: IL, interleukins; MFI, mean fluorescence intensity; MSC, skeletal (mesenchymal) stem cell.

sites where bone formation is needed. In vivo, TFAF2 expression was upregulated in the callus area during the inflammatory phase of fracture healing and also in the newly formed chondrocytes. This expression pattern is similar to what has been reported for other members of the C-C family. For example, it has been reported that CCL3 and CCL4 (MIP1- β) are expressed by the callus chondrocytes during fracture healing

[38]. The stimulating effects of TFAF2 on MSC in vitro transmigration, the increased expression of TFAF2 during fracture healing, and the absence of its direct effects of MSC differentiation suggest a possible role for in vivo chemotactic effects on MSC during fracture healing. Previous studies have shown that the number of osteoprogenitor cells in systemic circulation is increased after bone fracture [39]. It is thus plausible that the

presence of high levels of TFAF2 inside the bone fracture microenvironment during the inflammatory phase of fracture healing results in recruitment of osteoprogenitor cells needed for subsequent bone formation (Fig. 4L). Future studies are needed to determine whether local expression of TFAF2 at the fracture site could be used to increase recruitment of osteoprogenitors and to enhance the fracture healing.

CONCLUSION

We demonstrate that during the inflammatory phase of fracture healing, TFAF2 levels are increased at the site of fracture that leads to recruitment of osteogenic cells to the fracture site through activation of Rac1-p38 signaling.

ACKNOWLEDGMENTS

This study was supported by a grant from the Innovation Foundations, the Novo Nordisk Foundation (NNF15OC0016284), Denmark, and KACST (Project Code: 10-BIO1308-02). The

funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank Tina K. Nielsen, Bianca Jørgensen, Anita Friimose, and Charles E. Frary for excellent technical assistance. This article is dedicated to the loving memory of a wonderful physician, mentor, and scientist, Dr. Hans Johnsen.

AUTHOR CONTRIBUTIONS

A.J., A.I., L.C., N.D., W.Z., L.H., and C.C.: performed experiments, data analysis and interpretation; A.J., A.I., L.C., N.D., W.Z., L.H., H.E.J., B.M.A., C.C., and M.K.: conception/design, experimental design; H.E.J. provision of clinical samples; A.J., A.I., M.K.: manuscript writing; A.J., L.C., N.D., L.H., B.M.A., M.K.: manuscript editing. All authors: Final approval of manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.

REFERENCES

- Abdallah BM, Kassem M. Human mesenchymal stem cells: From basic biology to clinical applications. *Gene Ther* 2008;15:109–116.
- Abdallah BM, Jafari A, Zaher W et al. Skeletal (stromal) stem cells: An update on intracellular signaling pathways controlling osteoblast differentiation. *Bone* 2015;70:28–36.
- Granero-Molto F, Weis JA, Miga MI et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. *STEM CELLS* 2009;27:1887–1898.
- Sanghani-Kerai A, Coathup M, Samazideh S et al. Osteoporosis and ageing affects the migration of stem cells and this is ameliorated by transfection with CXCR4. *Bone Joint Res* 2017;6:358–365.
- Glass GE, Chan JK, Freidin A et al. TNF- α promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. *Proc Natl Acad Sci USA* 2011;108:1585–1590.
- Wang Y, Pati S, Schreiber M. Cellular therapies and stem cell applications in trauma. *Am J Surg* 2018;215:963–972.
- Pearlin S, Nayak G, Manivasagam DS. Progress of regenerative therapy in orthopedics. *Curr Osteoporos Rep* 2018;16:169–181.
- Verboket R, Leiblein M, Seebach C et al. Autologous cell-based therapy for treatment of large bone defects: from bench to bedside. *Eur J Trauma Emerg Surg* 2018;44:649–665.
- Yin Y, Li X, He XT et al. Leveraging stem cell homing for therapeutic regeneration. *J Dent Res* 2017;96:601–609.
- Pignolo RJ, Kassem M. Circulating osteogenic cells: implications for injury, repair, and regeneration. *J Bone Miner Res* 2011;26:1685–1693.
- Teo GS, Ankrum JA, Martinelli R et al. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor- α -activated endothelial cells via both leukocyte-like and novel mechanisms. *STEM CELLS* 2012;30:2472–2486.
- Levy O, Mortensen LJ, Boquet G et al. A small-molecule screen for enhanced homing of systemically infused cells. *Cell Rep* 2015;10:1261–1268.
- De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? *World J Stem Cells* 2016;8:73–87.
- Duffield JS, Park KM, Hsiao LL et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. *J Clin Invest* 2005;115:1743–1755.
- Iso Y, Spees JL, Serrano C et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. *Biochem Biophys Res Commun* 2007;354:700–706.
- Togel F, Hu Z, Weiss K et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. *Am J Physiol Renal Physiol* 2005;289:F31–F42.
- Steiner B, Roch M, Holtkamp N et al. Systemically administered human bone marrow-derived mesenchymal stem home into peripheral organs but do not induce neuroprotective effects in the MCAo-mouse model for cerebral ischemia. *Neurosci Lett* 2012;513:25–30.
- Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. *Nat Med* 2008;14:181–187.
- Guan M, Yao W, Liu R et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. *Nat Med* 2012;18:456–462.
- Tom Tang Y, Emtage P, Funk WD et al. TFAF: A novel secreted family with conserved cysteine residues and restricted expression in the brain. *Genomics* 2004;83:727–734.
- Borg K, Stankiewicz P, Bocian E et al. Molecular analysis of a constitutional complex genome rearrangement with 11 breakpoints involving chromosomes 3, 11, 12, and 21 and a approximately 0.5-Mb submicroscopic deletion in a patient with mild mental retardation. *Hum Genet* 2005;118:267–275.
- Walford GA, Gustafsson S, Rybin D et al. Genome-wide association study of the modified stumvoll insulin sensitivity index identifies BCL2 and FAM19A2 as novel insulin sensitivity loci. *Diabetes* 2016;65:3200–3211.
- Steffen A, Ladwein M, Dimchev GA et al. Rac function is crucial for cell migration but is not required for spreading and focal adhesion formation. *J Cell Sci* 2013;126:4572–4588.
- Reichel CA, Rehberg M, Lerchenberger M et al. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. *Arterioscler Thromb Vasc Biol* 2009;29:1787–1793.
- Tatara Y, Ohishi M, Yamamoto K et al. Macrophage inflammatory protein-1 β induced cell adhesion with increased intracellular reactive oxygen species. *J Mol Cell Cardiol* 2009;47:104–111.
- Yamagami S, Tamura M, Hayashi M et al. Differential production of MCP-1 and cytokine-induced neutrophil chemoattractant in the ischemic brain after transient focal ischemia in rats. *J Leukoc Biol* 1999;65:744–749.
- Krause M, Gautreau A. Steering cell migration: Lamellipodium dynamics and the regulation of directional persistence. *Nat Rev Mol Cell Biol* 2014;15:577–590.
- Weber KS, Klickstein LB, Weber PC et al. Chemokine-induced monocyte transmigration requires cdc42-mediated cytoskeletal changes. *Eur J Immunol* 1998;28:2245–2251.
- Chamberlain G, Smith H, Rainger GE et al. Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: Effects of

chemokines and shear. *PLoS One* 2011;6:e25663.

30 Belema-Bedada F, Uchida S, Martire A et al. Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. *Cell Stem Cell* 2008;2:566–575.

31 Reed MJ, Ferara NS, Vernon RB. Impaired migration, integrin function, and actin cytoskeletal organization in dermal fibroblasts from a subset of aged human donors. *Mech Ageing Dev* 2001;122:1203–1220.

32 Shi D, Li X, Chen H et al. High level of reactive oxygen species impaired mesenchymal stem cell migration via overpolymerization of F-actin cytoskeleton in systemic lupus erythematosus. *Pathol Biol (Paris)* 2014;62:382–390.

33 Xu X, Liu X, Long J et al. Interleukin-10 reorganizes the cytoskeleton of mature dendritic cells leading to their impaired biophysical properties and motilities. *PLoS One* 2017;12:e0172523.

34 Kim J, Kim W, Le HT et al. IL-33-induced hematopoietic stem and progenitor cell mobilization depends upon CCR2. *J Immunol* 2014;193:3792–3802.

35 Chen Y, Wei Y, Liu J et al. Chemotactic responses of neural stem cells to SDF-1alpha correlate closely with their differentiation status. *J Mol Neurosci* 2014;54:219–233.

36 Ryu CH, Park SA, Kim SM et al. Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. *Biochem Biophys Res Commun* 2010;398:105–110.

37 Saika S, Okada Y, Miyamoto T et al. Role of p38 MAP kinase in regulation of cell migration and proliferation in healing corneal epithelium. *Invest Ophthalmol Vis Sci* 2004;45:100–109.

38 Alblowi J, Tian C, Siqueira MF et al. Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. *Bone* 2013;53:294–300.

39 Eghbali-Fatourehchi GZ, Lamsam J, Fraser D et al. Circulating osteoblast-lineage cells in humans. *N Engl J Med* 2005;352:1959–1966.

40 Simonsen JL, Rosada C, Serakinci N et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. *Nat Biotechnol* 2002;20:592–596.

41 Abdallah BM, Haack-Sorensen M, Burns JS et al. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. *Biochem Biophys Res Commun* 2005;326:527–538.

42 Jafari A, Siersbaek MS, Chen L et al. Pharmacological Inhibition of protein kinase G1 enhances bone formation by human skeletal stem cells through activation of RhoA-Akt signaling. *STEM CELLS* 2015;33:2219–2231.

43 Jafari A, Qanie D, Andersen TL et al. Legumain regulates differentiation fate of human bone marrow stromal cells and is altered in postmenopausal osteoporosis. *Stem Cell Rep* 2017;8:373–386.

44 Hans Gottlieb TWK, Martin Boegsted BS, Olsen GS et al. Clinical study of circulating cellular and humoral biomarkers involved in bone regeneration following traumatic lesions. *J Stem Cell Res Ther* 2011;1:1–10.

45 Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. *J Orthop Res* 1984;2(1):97–101.



See www.StemCells.com for supporting information available online.